Kaufman Rossin Wealth LLC purchased a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) in the first quarter, HoldingsChannel reports. The firm purchased 6,519 shares of the biotechnology company’s stock, valued at approximately $461,000.
A number of other large investors have also added to or reduced their stakes in BMRN. Nuveen LLC acquired a new position in BioMarin Pharmaceutical in the 1st quarter valued at $184,475,000. Northern Trust Corp increased its position in shares of BioMarin Pharmaceutical by 16.2% in the fourth quarter. Northern Trust Corp now owns 1,725,039 shares of the biotechnology company’s stock worth $113,387,000 after purchasing an additional 240,681 shares during the period. Charles Schwab Investment Management Inc. raised its stake in BioMarin Pharmaceutical by 7.6% in the first quarter. Charles Schwab Investment Management Inc. now owns 1,532,314 shares of the biotechnology company’s stock valued at $108,319,000 after purchasing an additional 108,806 shares in the last quarter. AQR Capital Management LLC lifted its position in BioMarin Pharmaceutical by 114.5% during the fourth quarter. AQR Capital Management LLC now owns 1,283,599 shares of the biotechnology company’s stock worth $84,371,000 after purchasing an additional 685,099 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in BioMarin Pharmaceutical by 19.8% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,055,087 shares of the biotechnology company’s stock worth $69,351,000 after buying an additional 174,634 shares in the last quarter. Institutional investors and hedge funds own 98.71% of the company’s stock.
BioMarin Pharmaceutical Stock Up 1.1%
Shares of NASDAQ BMRN opened at $57.96 on Thursday. The company has a 50 day simple moving average of $57.43 and a 200 day simple moving average of $61.45. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.56 and a quick ratio of 3.60. BioMarin Pharmaceutical Inc. has a 1 year low of $52.93 and a 1 year high of $94.64. The firm has a market cap of $11.13 billion, a PE ratio of 17.20, a price-to-earnings-growth ratio of 0.74 and a beta of 0.18.
Analyst Upgrades and Downgrades
Get Our Latest Analysis on BioMarin Pharmaceutical
About BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
Featured Articles
- Five stocks we like better than BioMarin Pharmaceutical
- How to Buy Cheap Stocks Step by Step
- Toll Brothers: A Great Buy and Hold Stock With Risks in 2025
- What Are Dividend Challengers?
- Lowe’s Builds Value for Investors: Still a Good Buy in 2025
- The 3 Best Retail Stocks to Shop for in August
- Jackson Hole 2025: Fed’s Signal Could Shift Stocks Fast
Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report).
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.